Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial
Latest Information Update: 30 Mar 2020
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms DARALLO
Most Recent Events
- 25 Mar 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Jul 2019 New trial record